•				/ 012	6.)	١		
Substitute for form 14	49A/PTO & 14	498/PT	0 /	MAD 9 0 00		Com	plete if Known	
		IRS		B MAR 2 2 20	104	Application Number	10/633,438	
INFORMATION DISCLOSURE				SURE	ES.	Filing Date	August 1, 2003	
STATEMENT BY APPLICANTARY				First Named Inventor	Robert H. Oakley			
(use as many sheets as necessary)						Examiner Name	Unassigned	
Sheet	1	of		4		Attorney Docket Number	033072-044	

Examiner Initials		Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication 0 (MM-DD-YYYY)		
1		20020106739	A1	Oakley et al.	08-08-2002		
	1	20030049643	L	Barak et al.	03-13-2003		
	1	20040029190		Barak et al.	02-12-2004		
-1		20030013137		Barak et al.	01-16-2003		
$\neg 1$		6,096,705		Lefkowitz et al.	08-01-2000		
$\neg$		6,110,693		Barak, et al.	08-29-2000		
一		6,066,476		Tsien, et al.	05-23-2000		
一十		5,891,646		Barak, et al.	04-06-1999		
一十		5,777,079		Tsien, et al.	07-07-1998		
_		5,625,048		Tsien, et al.	04-29-1997		
一十		4,981,784		Evans, et al.	01-01-1991		
$\overline{}$		4,816,567		Cabilly, et al.	03-28-1989		
一十		4,493,890		Morris	01-15-1985		
		4,491,632		Wands, et al.	01-01-1985 09-18-1984		
$\neg \uparrow$		4,472,500		Milstein, et al.			
$\neg$		4,466,917		Nussenzweig, et al.	08-21-1984		
$\neg \vdash$		4,451,570		Royston, et al.	05-29-1984		
$\top$		4,444,887	·	Hoffmann	04-24-1984		
		4,427,783	.,	Newman, et al.	01-24-1984		
十		4,399,121		Albarella, et al.	08-16-1983		
$\neg$		4,342,566		Theofilopoulous, et al.	08-03-1982		
$\top$		4,341,761		Ganfield, et al.	07-27-1982		
$\neg$		4,016,043		Schuurs, et al.	04-05-1977		
$\top$		3,850,752		Schuurs, et al.	11-26-1974		
$\neg$		3,654,090		Schuurs, et al.	04-04-1972		
1		RE31,006		Schuurs, et al.	08-03-1982		
		4,816,397		Boss, et al.	03-28-1989		
		6,150,393		Behan, et al.	11-21-2000		
$\neg$	Ī	6,107,324		Behan, et al.	08-22-2000		
$\neg$		6,140,509		Behan, et al.	10-31-2000		
$\neg \uparrow$	1	5,989,835	<del> </del>	Dunlay, et al.	11-23-1999		
$\neg$		5,958,713		Thastrup, et al.	09-28-1999		
		5,804,387		Cormack, et al.	09-08-1998		
$\top$		5,491,084		Chalfie, et al.	02-13-1996		
		5,532,157		Fink	07-02-1996		
T		5,482,835		King, et al.	01-09-1996		
一	1	5,468,854		McCabe, et al.	11-21-1995		
$\top$	/	5,366,889		MacDonald, et al.	11-22-1994		
$\neg V$		5,284,746		Sledziewski, et al.	02-08-1994		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

## FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 10/633,438

Filing Date August 1, 2003

First Named Inventor Robert H. Oakley

Examiner Name Unassigned

Attorney Docket Number 033072-044

	(use as many	sheets	as necessary)	
Sheet	2	of		4

Substitute for form 1449A/PTO & 1449B/PTO

U.S. PATENT DOCUMENTS							
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)			
4/	5,576,436		McCabe, et al.	11-19-1996			

Examiner	Decument	Kind Code	FOREIGN PATENT DOCUI	Date of Publication	Translation	
Initials	Number	(if known)	Country	(MM-DD-YYYY)	Yes	No
4	02/059267	A2	WO	08-01-2002	]	
	88/03168	A1	WO	05-05-1988	]	
	01/58923	A2	wo	08-16-2001		
	98/44350	A1	WO	10-08-1998		
77	00/12704	A2	WO	03-09-2000	Ì	
	99/66324	A2	WO	12-23-1999		
17	94/16684	A1	wo	08-04-1994		
	98/12310	A1	WO	03-26-1998		

	NON-PATENT LITERATURE DOCUMENTS							
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, jour serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  WALKER, Julia K. L., et al., <i>Properties of Secretin Receptor Internalization Differ from Those of the β₂-Adrenergic Receptor*</i> , <u>Jou of Biological Chemistry</u> , Vol. 274, No. 44, October 29, 1999, pp. 31515-31523, The American Society for Biochemistry and Molec Biology, Inc., U.S.A.							
	Oakley et al., The Cellular Distribution of Fluorescently Labeled Arrestins Provides a Robust, Sensitive, and Universal Assay for Screening G Protein-Coupled Receptors, ASSAY and Drug Development Technologies, Vol. 1, No. 1-1, 2002, pp. 21-30.  ANGERS, S., et al., Detection of β <sub>2</sub> -Adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET), Proceedings of the National Academy of Sciences, Vol. 97, No. 7, March 28, 2000, pp. 3684-3689, Proc. Natl. Acad. Sci., USA.							
	ATTRAMADAL, H., et al., β <sub>2</sub> -Arrestin2, a Novel Member of the Arrestin/ β-Arrestin Gene Family, Journal of Biological Chemistry, Vol. 257, No. 25, September 5, 1992, pp 17882-17890, The American Society for Biochemistry and Molecular Biology, Inc., USA.							
	BARAK, et al., Abstract #2484, Molecular Biology of the Cell, Vol. 7, p. 427a December 1996, 6 International Congress on Cell Biology & 36 American Society for Cell Biology Annual Meeting, December 7 - 11, 1996, San Francisco, CA.							
	BARAK, L.S., et al., Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus, Proceedings of the National Academy of Sciences, Vol. 98, No. 1, January 2, 2001, pp. 93-98, Proc. Natl. Acad. Sci., USA.							
	BARAK, L.S., et al., A highly Conserved Tyrosine Residue in G Protein-Coupled Receptors is Required for Agonist-mediated β <sub>2</sub> -Adrenergic Receptor Sequestration, Journal of Biological Chemistry, Vol. 269, No. 4, January 28, 1994, pp. 2790-2795, The American Society for Biochemistry and Molecular Biology, Inc., USA.							
	BARAK, L.S., et al., A β-Arrestin/Green Fluorescent Protein Biosensor for Detecting G Protein-coupled Receptor Activation, Journal of Biological Chemistry, Vol. 272, No. 44, October 31, 1997, pp. 27497-27500, The American Society for Biochemistry and Molecular Biology, Inc., USA.							
	BARAK, L.S., et al., The Conserved Seven-Transmembrane Sequence NP(X) <sub>2.2</sub> Y of the G-Protein-Coupled Receptor Superfamily Regulates Multiple Properties of the β <sub>2</sub> -Adrenergic Receptor, <u>Biochemistry</u> , Vol. 34, No. 47,1995, pp. 15407-15414.							
	BARAK, L.S., et al., Internal Trafficking and Surface Mobility of a Functionally Intact β <sub>2</sub> -Adrenergic Receptor- Green Fluorescent Protein Conjugate, Molecular Pharmacology, 51, 1997, pp. 177-184.							
	BARAK, L.S., et al., Real-time Visualization of the Cellular Redistribution of G Protein-coupled Receptor Kinase 2 and β-arrestin 2 during Homologous Desensitization of the Substance P Receptor, Journal of Biological Chemistry, Vol. 274, No. 11, March 12, 1999, pp. 7565-7569, The American Society for Biochemistry and Molecular Biology, Inc., USA.							
	CUBITT, A., et al., Understanding, Improving and Using Green Fluorescent Proteins, Trends in Biochemical Sciences, International Union of Biochemistry and Molecular Biology, 448-455,1995, Elsevier Trends Journals, Oxford, UK.							
	DREWS, J., <i>Drug Discovery: A Historical Perspective</i> , <u>Science</u> , Vol. 287, March 17, 2000, pp. 1960-1964, American Association for the Advancement of Science, Washington, D.C.							

Examiner		^	Date	1 10100
Signature			Considered	1 / / / 9/ 06
*CVALINED	Initial if reference franklassed and			D. D. Co. S. C. S. Albardan B. and Landing B.

\*EXAMINER: Initial if reference/considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

## Substitute for form 1449A/PTO & 1449B/PTO Complete if Known **Application Number** 10/633,438 **FIRST** Filing Date **INFORMATION DISCLOSURE** August 1, 2003 STATEMENT BY APPLICANT First Named Inventor Robert H. Oakley **Examiner Name** Unassigned (use as many sheets as necessary) 033072-044 Sheet of **Attorney Docket Number**

	NON-PATENT LITERATURE DOCUMENTS
Examiner lettials	Include-name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  FERGUSON, S.S.G., et al., G-protein-coupled receptor regulation: role of G-protein-coupled receptor kinases and arrestins, Can. J.
V	Physiol. Pharmacol., Vol. 74, 1996, pp. 1095-1110, NRC, Canada.  FERGUSON, S.S.G., et al., Molecular Mechanisms of G Protein-Coupled Receptor Desensitization and Resensitization, Life
1	Sciences, XP-002076355, Vol. 62, pp.1561-1565, 1998, Elsevier Publication, USA.
	FERGUSON, S.S.G., et al., Role of Phosphorylation in Agonist-promoted β₂-Adrenergic Receptor Sequestration, Journal of Biological Chemistry, Vol. 270, No. 42, October 20, 1995, pp. 24782-24789, The American Society for Biochemistry and Molecular Biology, Inc., USA.
	FERGUSON, S.S.G., et al., Role of β-arrestin in Mediating Agonist-Promoted G Protein-Coupled Receptor Internalization, Science, Vol. 271, January 19, 1996, pp363-366.
	GRADY, E., et al., Mechanisms Attenuating Cellular Responses to Neuropeptides: Extracellular Degradation of Ligands and Desensitization of Receptors, The Journal of Investigative Dermatology Symposium Proceedings, Vol. 21, No. 1, pp. 69 - 75, August 1997, The Society of Investigative Dermatology, Inc.
	HARRIS, E., et al, <i>Protein Purification Methods</i> , pp.12-18, 1989, Oxford University Press, New York, U.S.
	HAUSDORFF, W.P., et al., A Mutation of the β₂-Adrenergic Receptor Impairs Agonist Activation of Adenylyl Cyclase without Affecting High Affinity Agonist Binding, Journal of Biological Chemistry, Vol. 265, No. 3, January 25, 1990, pp. 1388-1393, The American Society for Biochemistry and Molecular Biology, Inc., USA.
	KIM, KM., et al., Differential Regulation of the Dopamine D₂ and D₃ Receptors by G Protein-coupled Receptor Kinases and β-arrestins, Journal of Biological Chemistry, Vol. 276 No. 40, October 5, 2001, pp. 37409-97414, The American Society for Biochemistry and Molecular Biology, Inc., USA.
	LAPORTE, S. A., et al., The Interaction of $\beta$ -Arrestin with the AP-2 Adaptor Is Required for the Clustering of $\beta$ <sub>2</sub> -Adrenergic Receptor into Clathrin-coated Pits, Journal of Biological Chemistry, Vol. 275, No. 30, July 28, 2000, pp. 23120-23126. The American Society for Biochemistry and Molecular Biology, Inc., USA.
	LAPORTE, S.A., et al., The β <sub>2</sub> -Adrenergic Receptor/β-arrestin complex recruits the clathrin adaptor AP-2 during endocytosis, <u>Proceedings of the National Academy of Sciences</u> , Vol. 96, No. 7, March 30, 1999, pp. 3712-3717, Proc.Natl. Acad. Sci, USA.
	LOHSE, M., et al., β-Arrestin: A Protein That Regulates β-Adrenergic Receptor Function, Science, Vol. 248, pp. 1547-1550, June 22, 1990.
	MCCONALOGUE, K., et al., Activation and Internalization of the µ-opioid Receptor by the Newly Discovered Endogenous Agonists, Endomorphin-1 and Endomorphin-2, Neuroscience, Vol. 90, No. 3, pp. 1051-1059, 1999, Elsevier Science Ltd., Great Britain.
	MCCONALOGUE, K., et al., Cellular and Subcellular Localization of G-Protein Receptor Kinases, Arrestins and G-Proteins: Implications for Receptor Regulation, Supplement to Gastroenterglogy, Digestive Disease Week and the 96 <sup>th</sup> Annual Meeting of the American Gastroenerological Association, Vol. 110, No. 4, April 1996.
	MCCONALOGUE, K., et al., G Protein-Coupled Receptors in Gastrointestinal Physiology II. Regulation of Neuropeptide receptors in enteric neurons, Receptor Regulation, pp. G792-G796, 1998, American Physiological Society.
	MCCONALOGUE, K., et al., Substance P-induced Trafficking of β-arrestins, Journal of Biological Chemistry, Vol. 274, No. 23, pp.16257-16268, June 4, 1999, The American Society for Biochemistry and Molecular Biology, Inc., USA.
	MÉNARD, L., et al., Members the G Protein-Coupled Receptor Kinase Family that Phosphorylate the β <sub>Z</sub> -Adrenergic Receptor Facilitate Sequestration, Biochemistry, Vol. 35, No. 13, 1996, pp. 4155-4160, The American Chemical Society.
	MÉNARD, L., et al., Synergistic Regulation of β <sub>2</sub> -Adrenergic Receptor Sequestration: Intracellular Complement of β <sub>2</sub> -Adrenergic Receptor Kinase and β <sub>2</sub> -Adrestin Determine Kinetics of Internalization, Molecular Pharmacology, Vol. 51, No. 5, May 1997, pp. 800-808, The American Society for Pharmacology and Experimental Therapeutics.
	MHAOUTY-KODJA, S., et al., Constitutively Active Alpha-1b Adrenergic Receptor Mutants Display Different Phosohorylation and Internalization Features, Molecular Pharmacology, Vol. 55, No. 2, February 1999, pp. 339-347, The American Society for Pharmacology and Experimental Therapeutics.
	ORMÖ, M., et al., Crystal Structure of the Aequorea victoria Green Fluorescent Proteins, Science, Vol. 273, pp. 1392-1395, 1996, American Association for the Advancement of Science, Washington D.C.
	OAKLEY, R.H., et al., Association of β-Arrestin with G Protein-coupled Receptors during Clathrin-mediated Endocytosis Dictates the Profile of Receptor Resensitization, Journal of Biological Chemistry, Vol. 274, No. 45, November 5, 1999, pages 17201-17210, The American Society for Biochemistry and Molecular Biology, Inc., USA.

				The second secon				
Examiner				Date		<del>- / /,</del>	0/1	
Signature		¥		Consid	tered		7/6/	3
*EXAMINER:	Initial if referen	ce considered	whether or not cit	ation is in conformat	CO with M D E D &	600 /Drow 1	no through	citation if not in

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Substitute for form 1	449A/PTO & 1	449B/PT	0	Complete if Known			
	ı	FIRS	T	Application Number	10/633,438		
INFO	RMATIC	ON [	DISCLOSURE	Filing Date	August 1, 2003		
STATEMENT BY APPLICANT (use as many sheets as necessary)			APPLICANT	First Named Inventor	Robert H. Oakley		
			as necessary)	Examiner Name	Unassigned		
Sheet	4	of	4	Attorney Docket Number	033072-044		

	NON-PATENT LITERATURE DOCUMENTS							
Examin Initials								
2	OAKLEY, R.H., et al., Differential Affinities of Visual Arrestin, β-Arrestin1, and β-Arrestin2 for G Protein-coupled Receptors Delineate Two Major Classes of Receptors, Journal of Biological Chemistry, Vol. 275, No. 22, June 2, 2000, pp. 17201-17210, The American Society for Biochemistry and Molecular Biology, Inc., USA.							
1	OAKLEY, R.H., et al., Molecular Determinants Underlying the Formation of Stable Intracellular G Protein-coupled Receptor – β-Arrestin Complexes after Receptor Endocytosis, Journal of Biological Chemistry, Vol. 276, No. 22, June 1, 2001, pp. 19452 - 19460, The American Society for Biochemistry and Molecular Biology, Inc., USA.							
$\mathcal{T}$	YOKOE, Spatial Dynamics of GFP-tegged proteins investigated by local fluorescence enhancement, Nature Biotechnology, Vol. 14, pp. 1252 - 1256, October 14, 1996.							
	ZHANG, J., et al., Cellular Trafficking of G Protein-coupled Receptor/ β-Arrestin Endocytic Complexes, Journal of Biological Chemistry, Vol. 274, No. 16, April 16, 1999, pp. 10999-11006, The American Society for Biochemistry and Molecular Biology, Inc., USA.							
	ZHANG, J., et al., A Central Role for β-Arrestins and Clathrin-coated Vesicle-mediated Endocytosis in β <sub>2</sub> -Adrenergic Receptor Resensitization, Journal of Biological Chemistry, Vol. 272, No. 43, October 24, 1997, pp. 27005-27014, The American Society for Biochemistry and Molecular Biology, Inc., USA.							

		1			•	
Examiner	77		Date		10/	2
Signature	y		Considered	//	19/	06
*E-VA NAINTED: 1-101-1-17						